Frances M. Palmieri - Concepedia

Author

Frances M. Palmieri

Mayo Clinic in Florida

Also Known As

F Palmieri, F. M. Palmieri, F. Palmieri, F.M. Palmieri, Frances M Palmieri, Frances M. Palmieri

Publications

576

Citations

H-Index

Concepts

All Affiliations

Mayo Clinic in Florida Mayo Clinic Mayo Clinic in Arizona WinnMed Dayton Clinical Oncology Program

About

Frances M. Palmieri is an author at Mayo Clinic in Florida specializing in medicine, breast cancer, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	308
2	Pharmacology	6	6	259
3	Obstetrics	2	2	49
4	Pathology	2	2	35
5	Surgical Oncology	1	1	20

Frances M. Palmieri

Publications

352

Citations

H-Index

Page 1

	Year	Citations
Phase II trial of weekly nab (nanoparticle albumin-bound)-paclitaxel (nab-paclitaxel) (Abraxane®) in combination with gemcitabine in patients with metastatic breast cancer (N0531) Vivek Roy, Betsy LaPlant, Gerald G. Gross, Annals of Oncology Metastatic Breast CancerBreast OncologyPhase Ii TrialMedicinePharmacology	2008	144
Prognosis and Outcome of Small (≤1 cm), Node-Negative Breast Cancer on the Basis of Hormonal and HER-2 Status Surabhi Amar, Ann E. McCullough, Winston Tan, The Oncologist	2010	44
North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer Edith A. Perez, David W. Hillman, Todor Dentchev, Annals of Oncology Metastatic Breast CancerBreast OncologyPhase Ii TrialMedicinePharmacology	2009	44
Comprehensive Diagnostic Program for Medically Underserved Women With Abnormal Breast Screening Evaluations in an Urban Population Frances M. Palmieri, Elizabeth R. DePeri, Betty A. Mincey, Mayo Clinic Proceedings Cancer DetectionCancer ScreeningUrban PopulationMedically Underserved WomenDiagnosis	2009	36
Anthracycline vs nonanthracycline adjuvant therapy for breast cancer. Dina K. Tack, Frances M. Palmieri, Edith A. Perez PubMed Surgical OncologyOncologyBreast Cancer ResearchBreast OncologyMolecular Markers	2004	20
RC0639: phase II study of paclitaxel, trastuzumab, and lapatinib as adjuvant therapy for early stage HER2-positive breast cancer Alvaro Moreno‐Aspitia, Amylou C. Dueck, Ismael Ghanem-Cañete, Breast Cancer Research and Treatment Breast OncologyMedicinePharmacologyPathologyPhase Ii Study	2013	18
BAY 43–9006 as single oral agent in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane Alvaro Moreno‐Aspitia, David W. Hillman, Martin Wiesenfeld, Journal of Clinical Oncology Pdgfr-β Growth FactorsMetastatic Breast CancerSingle Oral AgentBreast OncologyMedicine	2006	17
N0332 phase 2 trial of weekly irinotecan hydrochloride and docetaxel in refractory metastatic breast cancer: a North Central Cancer Treatment Group (NCCTG) Trial Winston Tan, David W. Hillman, Muhammad Salim, Annals of Oncology Breast OncologyMedicinePharmacologyN0332 Phase 2Breast Cancer	2009	16
Comprehensive Diagnostic Program for Medically Underserved Women With Abnormal Breast Screening Evaluations in an Urban Population Frances M. Palmieri, Elizabeth R. DePeri, Betty A. Mincey, Mayo Clinic Proceedings Cancer DetectionCancer ScreeningUrban PopulationMedically Underserved WomenDiagnosis	2009	13

Page 1